The relationship between Cemiplimab and Cemiplimab

Cemiplimab（Cemiplimab) is essentially Cemiplimab, and the two names refer to the same drug. Cemiplimab is its Chinese trade name, while Cemiplimab is its international common name or English name. Globally, during the development and registration process of pharmaceutical companies, drugs usually have international common names (INN) and trade names registered in various countries. Cemiplimab belongs to the PD-1 inhibitor class of monoclonal antibody drugs. Its main mechanism of action is to relieve the immune suppression of T cells by cancer cells and achieve the elimination of tumors by the immune system by blocking the PD-1 signaling pathway. This mechanism shows good anti-tumor activity in indications such as locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC), and non-small cell lung cancer (NSCLC).

Cemiplimab andCemiplimab are completely identical in ingredients, dosage specifications and clinical uses. Patients may see both Chinese and English names when learning about drugs, but their pharmacological properties, efficacy and safety are exactly the same. The common specification is 350mg/7mL (50mg/mL) for intravenous injection, which is used for adult patients who meet the indications. The research and development, production and quality control of drugs are all completed by the original research company to ensure drug efficacy and safety. Overseas marketed versions include original drugs approved by the US FDA and drugs approved by the European EMA, but they have not yet been launched or covered by medical insurance in China, so patient acquisition channels are mainly through overseas medical institutions or clinical trial channels.

Patients should be concerned about potential adverse reactions when using cimepilimab, including immune-related skin, liver, lung, and endocrine system problems. Doctors will monitor and adjust dosage according to the patient's individual condition to ensure efficacy and safety. In short, whether it is called cemiplimab or Cemiplimab, the drug itself is exactly the same, and patients can treat it as the same immunotherapy drug when understanding the drug, which facilitates rational drug use and follow-up management.

Reference materials:https://www.libtayohcp.com/